Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2021
The study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18 years of age.
Epistemonikos ID: 17717c2a609840063d31abbf56f32ef285457be2
First added on: Feb 15, 2022